Text this: Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study

  _____     ______               ___     __   _   
 / ____||  /_   _//   ____      / _ \\  | || | || 
/ //---`'   -| ||-   |    \\   / //\ \\ | '--' || 
\ \\___     _| ||_   | [] ||  |  ___  ||| .--. || 
 \_____||  /_____//  |  __//  |_||  |_|||_|| |_|| 
  `----`   `-----`   |_|`-`   `-`   `-` `-`  `-`  
                     `-`